Leiden, The Netherlands, September 9, 2002 - Dutch antibody and vaccine company, Crucell N.V. (Euronext, NASDAQ: CRXL), today announced management changes. Dr. Jaap Goudsmit, currently Chief Medical Officer, succeeds Dr. Ton Logtenberg as Chief Scientific Officer, commencing September 9, 2002. Dr. Goudsmit will be responsible for all R&D activities of Crucell.

 

Dr. Logtenberg has been appointed external advisor to Crucell. In this capacity Dr. Logtenberg will continue to focus on antibody research & intellectual property, thus contributing to the further growth of Crucell.

 

Prior to joining Crucell in September 2001, Dr. Goudsmit held various positions at the Academic Medical Center at the University of Amsterdam, most recently as chairman of the Research Institute for Infectious Diseases. Dr. Goudsmit is co-founder of both IAVI (International AIDS Vaccine Initiative), the premier non-governmental driving force for a global HIV vaccine, and EuroVac, the European Union AIDS vaccine effort.

 

About Crucell

Crucell discovers and develops biopharmaceuticals that use the human immune system to combat cancer, infectious diseases and other conditions.  Crucell leverages its patented technologies, MAbstract(TM), AdVac(TM), and PER.C6(TM), for discovery, development and production of antibodies and vaccines.  Crucell offers its technologies to the pharmaceutical and biotechnology industry and also uses them to create its own product pipeline.  Partners include Merck & Co. for the HIV vaccine, the National Institutes of Health (NIH) for the Ebola vaccine and Centocor, a Johnson & Johnson company, for the CD46 antibody for treatment of various types of cancer.  In addition, Crucell has over 20 licensees for its PER.C6(TM) technology.  These include Novartis, GSK, Aventis and Schering AG.  With headquarters in Leiden, The Netherlands, the company currently employs 200 people.  Crucell is listed on Euronext and NASDAQ (ticker symbol CRXL).  For more information visit www.crucell.com.

 

Please click on the link to view the formatted article: